Compare Corning Incorporated (GLW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs TG Therapeutics Inc — how do they compare? Corning Incorporated trades at $156.5 (market cap $131.65B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Corning Incorporated is far larger — about 16.1× TG Therapeutics Inc's market cap, and Corning Incorporated pays a 0.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and TG Therapeutics Inc for 16 Days on average.
| GLW | TGTX | |
|---|---|---|
Market Cap | $131.65B | $8.16B |
Volume | 8,992,522 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $255.79 | $59.06 |
52-Week Low | $78.03 | $26.94 |
Typical Hold Time | 36 Days | 16 Days |
Enterprise Value | $138.52B | $8.37B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $156.69, down 3.99% amid a bearish technical signal, though fundamentals show strong recovery with 2025 revenue reaching $15.63B and net income surging to $1.60B. The company recently secured a multi-year $3B fiber supply deal with AT&T, boosting its optical communications segment. Analyst consensus remains positive with a $171.25 price target and 57% buy ratings, but technical indicators show selling pressure with support at $149.
GLW presents a mixed outlook: the AT&T deal and earnings beat streak support growth, but high valuation ratios (P/E 70.43) and bearish technicals pose near-term risks. Investors should weigh strong cash flow projections ($1.0B net CF in 2026) against patent litigation concerns and elevated debt levels. The stock offers upside to analyst targets if execution continues.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
